Updated Risk Assessment on Ashwagandha: Health Concerns and Safety Recommendations

The BfR published a risk assessment in 2012 on Withania somnifera (ashwagandha) due to concerns about thyroid interference and its historical use as an abortifacient. Recent studies (2020-2024) by European and Australian institutions confirm these concerns and highlight additional risks, including effects on blood glucose, sex hormones, the central nervous system, and liver function. Reports of adverse effects, such as liver damage and digestive issues, have emerged, particularly in individuals with pre-existing liver conditions. Ashwagandha supplements can also interact with medications. Given insufficient safety data, especially for pregnant women, breastfeeding mothers, and children, European authorities advise against using these supplements.